Amid ongoing battles over alternate provides of blockbuster weight reduction medicine, Eli Lilly filed new lawsuits in opposition to 4 telehealth companies and their associates, however is utilizing a brand new line of assault — the drugmaker accused two of the businesses of partaking within the company follow of medication.
So far, Lilly and its rival, Novo Nordisk, have filed dozens of fits in opposition to quite a few corporations concerned in compounding variations of semaglutide and tirzepatide, the weight problems and diabetes medicine generally known as GLP-1s. For the previous three years, telehealth companies, compounding pharmacies, and med spas have partnered to fabricate, prescribe and distribute copies of the medicine whereas shortages existed. These lawsuits alleged trademark infringement, false claims and unfair competitors, however have to this point yielded various outcomes.
This time, Lilly has alleged two corporations, Mochi Well being and Fella Well being, engaged within the company follow of medication, which refers to controlling and influencing prescribing choices of well being care suppliers. They purportedly did so with the assistance of affiliated medical teams and compounding pharmacies, based on separate lawsuits filed on Wednesday within the U.S. District Courtroom for the Northern District of California.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
